Multiple sclerosis drugs cost between $57,000 and $93,000 per person per year, making them the single largest medical expense for people living with MS. That price tag isn’t driven by any one factor. It’s the result of how these drugs are made, how the U.S. drug market operates, and how little price competition exists in the MS treatment space.
What MS Drugs Actually Cost
Disease-modifying therapies, the medications that slow MS progression, range from $57,202 to $92,719 per person annually, according to the National MS Society. The exact figure depends on the specific drug, patient age, and gender. These are list prices, meaning the sticker price before insurance negotiations and rebates. The amount a patient actually pays varies widely based on their coverage, but even with insurance, annual out-of-pocket costs for MS drugs can reach thousands of dollars due to high deductibles and specialty drug copays.
Biologic Drugs Are Expensive to Produce
Many of the newer and most effective MS therapies are biologics, meaning they’re made from living cells rather than simple chemical compounds. A traditional pill can be synthesized in a straightforward chemical process. A biologic requires growing proteins inside living cells housed in massive, carefully controlled bioreactors. The production environment has to be kept within extremely tight conditions because even small changes can alter the final product.
The cost difference between these two approaches is dramatic. Simple oral medications can be manufactured for as little as a few cents per dose. Biologic infusion drugs, by contrast, can cost hundreds of dollars per dose just to produce. That manufacturing gap is real, but it doesn’t come close to explaining a $70,000 annual price tag. Production costs account for only a fraction of what patients and insurers pay.
Shadow Pricing Keeps Older Drugs Expensive
One of the most frustrating dynamics in MS drug pricing is a practice called shadow pricing. When a company launches a new MS drug at a high price, competitors don’t lower the prices of their older drugs to compete. Instead, they raise them to match. Congressional lawmakers have directly questioned seven pharmaceutical companies about this practice, asking them to explain why prices for existing MS medications climb in lockstep with newer, more expensive competitors entering the market.
This happens because MS drugs don’t compete on price the way most consumer products do. Doctors choose treatments based on a patient’s disease activity, side effect profile, and how well they tolerate a drug. Insurers negotiate rebates behind the scenes, but the list prices all float upward together. The result is that drugs originally launched at more modest prices years ago now cost nearly as much as the newest options.
The U.S. Pays Far More Than Other Countries
American patients and insurers pay dramatically more for the same medications than people in other wealthy countries. Across all drugs, U.S. prices in 2022 were 278 percent of the average price in 33 other developed nations. For brand-name drugs specifically, the gap is even wider: U.S. prices were 422 percent of prices in other countries.
Canadian prices for the same drugs run about 44 percent of what Americans pay. France and Japan consistently have the lowest prices among wealthy nations. The core difference is that most other countries have government agencies that negotiate drug prices directly with manufacturers or set price ceilings. The U.S. has historically allowed manufacturers to set their own prices, and insurers negotiate individually with limited leverage. The Inflation Reduction Act gave Medicare the ability to negotiate prices on some drugs starting in 2026, but most MS therapies haven’t been included in early rounds of negotiation.
Rebates Hide the Real Price
The prices patients see aren’t always what insurers ultimately pay. Pharmacy benefit managers, the middlemen who manage drug coverage for health plans, negotiate rebates from manufacturers. These rebates are essentially delayed discounts: the insurer pays the list price upfront, and the manufacturer returns a percentage later. PBMs charge a fee for this service, typically a percentage of the rebate itself.
The problem is that these rebates don’t always reach patients. Your copay or coinsurance is often calculated based on the full list price, not the discounted price your insurer eventually pays. So even when insurers get a 20 percent rebate on a $70,000 drug, a patient with 20 percent coinsurance still faces a bill calculated from that $70,000 figure. This system creates a perverse incentive: manufacturers can raise list prices while offering larger rebates to keep insurers happy, all while patients absorb higher out-of-pocket costs.
Limited Generic and Biosimilar Competition
Generic versions exist for some older MS drugs, including generic forms of Copaxone, Gilenya, Tecfidera, and Aubagio. These generics can reduce costs significantly. But the newer, more widely prescribed biologic therapies don’t yet face much biosimilar competition. A biosimilar is the biologic equivalent of a generic, a near-identical copy made by a different manufacturer.
Creating biosimilars is far more complex and expensive than making generic pills. Because biologics are produced by living cells, a competitor can’t simply copy the chemical formula. They have to demonstrate through extensive testing that their version works the same way in the body. This process takes years and costs hundreds of millions of dollars, which limits how many companies attempt it. Until more biosimilars reach the market for the most popular MS infusion therapies, meaningful price competition for those drugs will remain limited.
Patent Strategies Extend Exclusivity
Pharmaceutical companies use legal strategies to maintain market exclusivity well beyond a drug’s original patent. By filing additional patents on manufacturing processes, delivery methods, or specific dosing schedules, a company can create a thicket of legal protections that delay generic or biosimilar competitors for years. Some MS drugs have had their effective monopoly period extended significantly through these tactics.
Orphan drug designations add another layer. The FDA grants seven years of market exclusivity to drugs that treat rare diseases. While MS as a whole isn’t classified as rare, specific subtypes or uses can qualify for orphan status. This designation also comes with tax credits for clinical trials and exemptions from certain regulatory fees, all of which reduce a manufacturer’s costs while extending the period during which no competitor can sell an equivalent product.
R&D Costs Are Real but Overstated
Drug companies consistently point to research and development costs to justify high prices. Developing a new MS therapy does require massive investment. Clinical trials for MS drugs are particularly expensive because the disease progresses slowly, meaning trials must run for years and enroll thousands of patients to demonstrate that a drug reduces relapse rates or slows disability. Many drug candidates fail before reaching the market, and companies argue that the winners must pay for the losers.
This argument has some merit, but it doesn’t hold up as the primary explanation. Many of the most expensive MS drugs have been on the market for a decade or more, meaning their development costs have long been recouped. Prices continue to rise anyway. And the practice of shadow pricing, where companies raise prices on drugs that required no additional R&D investment, undermines the claim that prices simply reflect what it cost to bring a drug to market.
The reality is that MS drugs are expensive because several forces push prices up simultaneously and very few push them down. Complex manufacturing, thin competition, a U.S. regulatory environment that gives manufacturers significant pricing power, and an insurance system that obscures the true cost from patients all contribute. Until biosimilar competition expands and pricing transparency improves, the cost of treating MS will remain one of the most financially burdensome aspects of the disease.